References
- AOKI, H., OnsitimA, Y., TANAKA, M., OKAZAKI, 0. and HAKUSUI, H., 1994, High-performance liquid chromatographic determination of the new quinolone antibacterial agent DU-6859a in human serum and urine using solid-phase extraction with phoyolysis-fluorescence detection. Journal of Chromatography B, 660, 365–374.
- CRAIG, W. A., 1998, Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clinical Infectious Diseases, 26, 1–12.
- FELDMAN, C., WHITE H., O'GRADY, J., BRIGGS, A. and RICHARDS, G., 2001, An open, randomised, multi-centre study comparing the safety and efficacy of sitafloxacin and irnipenem/cilastatin in the intravenous treatment of hospitalised patients with pneumonia. Journal of Antimicrobial Agents, 17, 177–188.
- MATSUMOTO, M., KOJIMA, K., NAGANO, H., MATSUBARA, S and YOKOTA, T., 1992, Photostability and biological activity of fluoroquinolones substituted at 8 position after UV irradiation. Antimicrobial Agents and Chemotherapy, 36, 1715–1719.
- MILATOVIC, D., SCHMITZ, F.-J., BRISSE, S. VERHOEF, J and FLUIT, A. C., 2000, In vitro activities of sitafloxacin (DU-6859a) and six other fluoroquinolones against 8,796 clinical bacterial isolates. Antimicrobial Agents and Chemotherapy, 44, 1102–1107.
- SHETTY, N and WILSON, A. P. R., 2000, Sitafloxacin in the treatment of patients with infections caused by vancomycin-resistant enterococci (VRE) and methicillin-resistant Staphylococcus aureus. Journal of Antimicrobial Chemotherapy, 46, 633–638.